Valeria Difilippo

Valeria Difilippo

Auto-generated profile, based on publicly available information

Valeria Difilippo

Department of Laboratory Medicine, Division of Clinical Genetics, Lund University, Lund, Sweden

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2023 in Laboratory Investigation
Verified
Journal Article
Open access
VDValeria Difilippo
Valeria Difilippo
KSKarim H. Saba
Karim H. Saba
ESEmelie Styring
Emelie Styring
LMLinda Magnusson
Linda Magnusson
JNJenny Nilsson
Jenny Nilsson
KNKarolin H. Nord
Karolin H. Nord
Osteosarcoma is the most common primary bone malignancy, often detected in children and adolescents and commonly associated with TP53 alterations along with a high number of chromosomal rearrangements. However, osteosarcoma can affect patients of any age, and some tumors display less genetic complexity. Besides TP53 variants, data on key driving mutations are lacking for many osteosarcomas, particularly those affecting adults. To detect osteosarcoma-specific alterations, we screened transcriptomic and genomic sequencing and copy number data from 150 bone tumors originally diagnosed as osteosarcomas. To increase the precision in gene fusion detection, we developed a bioinformatic tool denoted as NAFuse, which extracts gene fusions that are verified at both the genomic and transcriptomic levels. Apart from the already reported genetic subgroups of osteosarcoma with TP53 structural variants, or MDM2 and/or CDK4 amplification, we did not identify any recurrent genetic driver that signifies the remaining cases. Among the plethora of mutations identified, we found genetic alterations characteristic of, or similar to, those of other bone and soft tissue tumors in 8 cases. These mutations were found in tumors with relatively few other genetic alterations or in adults. Due to the lack of clinical context and available tissue, we can question the diagnosis only on a genetic basis. However, our findings support the notion that osteosarcomas with few chromosomal alterations or adult onset seem genetically distinct from conventional osteosarcomas of children and adolescents.

25 September 2024 in npj Genomic Medicine
Verified
Journal Article
Open access
PDF file
KSKarim H. Saba
Karim H. Saba
VDValeria Difilippo
Valeria Difilippo
ESEmelie Styring
Emelie Styring
JNJenny Nilsson
Jenny Nilsson
LMLinda Magnusson
Linda Magnusson
KNKarolin H. Nord
Karolin H. Nord
Amplification of the MDM2 and CDK4 genes on chromosome 12 is commonly associated with low-grade osteosarcomas. In this study, we conducted high-resolution genomic and transcriptomic analyses on 33 samples from 25 osteosarcomas, encompassing both high- and low-grade cases with MDM2 and/or CDK4 amplification. We discerned four major subgroups, ranging from nearly intact genomes to heavily rearranged ones, each harbouring CDK4 and MDM2 amplification or CDK4 amplification with TP53 structural alterations. While amplicons involving MDM2 exhibited signs of an initial chromothripsis event, no evidence of chromothripsis was found in TP53-rearranged cases. Instead, the initial disruption of the TP53 locus led to co-amplification of the CDK4 locus. Additionally, we observed recurring promoter swapping events involving the regulatory regions of the FRS2, PLEKHA5, and TP53 genes. These events resulted in ectopic expression of partner genes, with the ELF1 gene being upregulated by the FRS2 and TP53 promoter regions in two distinct cases.

29 November 2025 in The Journal of Molecular Diagnostics
Verified
Journal Article
Open access
KWKarin Wallander
Karin Wallander
YLYingbo Lin
Yingbo Lin
VIVadym Ivanchuk
Vadym Ivanchuk
VDValeria Difilippo
Valeria Difilippo
VCVenkatesh Chellappa
Venkatesh Chellappa
FFFelix Haglund de Flon
Felix Haglund de Flon
Optical genome mapping (OGM) enables high-resolution detection of structural variants (SVs) and copy number aberrations (CNAs) using ultra-long DNA molecules and minimal bioinformatics processing. Its diagnostic utility in solid tumors remains underexplored. Whole-genome sequencing (WGS) offers comprehensive variant detection but is resource-intensive. This study presents a technical benchmarking of OGM versus WGS for mesenchymal tumors of the gynecological tract. We prospectively analyzed 25 uterine mesenchymal tumors using matched WGS, transcriptome sequencing, and OGM. Detected SVs, CNAs, and fusion genes were compared across platforms. OGM identified structural driver events in 80% of cases and demonstrated high concordance with WGS for major CNAs and translocations. In select cases, OGM resolved complex rearrangements not clearly defined by WGS, including a PLAG1::RERE fusion and an embedded inversion in a RAD51B::HMGA2 event. Conversely, WGS uniquely detected a truncating NF1 translocation and a TSC2::SENP3 fusion, both clinically significant. OGM is a technically robust platform for SV and CNA detection in mesenchymal tumors, and may serve as an efficient alternative to sequencing-based cytogenomic approaches in selected clinical contexts, especially in tumors known to be driven by gross chromosomal rearrangements. WGS provides a comprehensive view of the cancer genome, suitable for tumors driven by both single nucleotide variants, SVs, and CNAs. The choice between platforms should be guided by clinical context, diagnostic needs, and available resources.

1 April 2026 in Cancer Research Communications
Verified
Journal Article
Open access
ETElisa Tirtei
Elisa Tirtei
VDValeria Difilippo
Valeria Difilippo
FDFederico Divincenzo
Federico Divincenzo
SASebastian Dorin Asaftei
Sebastian Dorin Asaftei
NRNicola Ratto
Nicola Ratto
Franca FagioliFranca Fagioli
Franca Fagioli
Sarcomas in pediatric and adolescent–young adult (AYA) populations represent rare and biologically heterogeneous tumors with complex genetic underpinnings. Genomic profiling reveals subtype-specific alterations and therapeutic targets. Such tumors still represent an unmet clinical need due to limited treatment options and poorer outcomes, especially in advanced stages. Here, we present the SAR-GEN2016 and SAR-GEN_ITA clinical trials, conducted across 12 Italian centers, which enrolled 201 patients, including 158 bone and soft-tissue sarcoma samples collected at diagnosis or relapse. Whole-exome sequencing was successfully performed on 120 tumor samples. The most representative histotypes were osteosarcoma (n = 53), Ewing sarcoma (n = 39), rhabdomyosarcoma (n = 13), and synovial sarcoma (n = 5), and the genomic analyses were mainly focused on these subtypes. Overall, our cohort showed genomic differences between subtypes, highlighting how genomic complex sarcomas and fusion-driven sarcomas are distinct entities. The genomic complex histotypes, such as osteosarcoma, were characterized by a lower tumor mutational burden (TMB) and higher copy-number variation burden with enrichment of the CN2 signature. Recurrent and metastatic Ewing sarcomas have a higher TMB compared with treatment-naïve primary tumors, along with increased intratumoral heterogeneity. Oncogenic pathway analyses revealed dysregulation of the RTK–RAS and NOTCH pathways across subtypes, particularly in metastatic and recurrent tumors. In 71 of 120 analyzed samples (59%), at least one potentially actionable genomic alteration was identified, and 16% of those patients with relapsed disease received a matched targeted therapy based on the molecular profiling results. All findings were classified as ESCAT tier II or III. Our findings support the value of integrating genomic and clinical data to accelerate translational research in rare tumors. Significance: Pediatric and AYA sarcomas are rare with poor outcomes in advanced stages and limited treatment options. Through the SAR-GEN2016 and SAR-GEN_ITA multicenter trials, we performed whole-exome sequencing on 120 tumor samples with matched normal tissue from 158 patients with bone and soft-tissue sarcoma. Our integrative genomic analysis supports the genomic stratification and precision oncology in rare pediatric sarcomas.

20 April 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
KSKarim H. Saba
Karim H. Saba
VDValeria Difilippo
Valeria Difilippo
MKMichal Kovac
Michal Kovac
LCLouise Cornmark
Louise Cornmark
LMLinda Magnusson
Linda Magnusson
KNKarolin H. Nord
Karolin H. Nord
How massive genome rearrangements confer a competitive advantage to a cancer cell has remained an enigma. The malignant bone tumour osteosarcoma harbours an extreme number of structural variations and thereby holds the key to understand complex cancer genomes. Genome integrity in osteosarcoma is generally lost together with disruption of normal TP53 gene function, the latter commonly through either missense mutations or structural alterations that separate the promoter region from the coding parts of the gene. To unravel the consequences of a TP53 promoter relocated in this manner, we performed in-depth genetic analyses of osteosarcoma biopsies ( n =148) and cell models. We show that TP53 structural variations are early events that not only facilitate further chromosomal alterations, but also allow the TP53 promoter to upregulate genes erroneously placed under its control. Paradoxically, many of the induced genes are part of the TP53 -associated transcriptome, suggesting a need to counterbalance loss of TP53 function through ‘separation-of-function’ mutations via promoter swapping. Our findings demonstrate how massive genome errors can functionally turn the promoter region of a tumour suppressor gene into a constitutively active oncogenic driver.

17 June 2026
Verified
Other
Open access
ETElisa Tirtei
Elisa Tirtei
VDValeria Difilippo
Valeria Difilippo
FDFederico Divincenzo
Federico Divincenzo
SASebastian Dorin Asaftei
Sebastian Dorin Asaftei
NRNicola Ratto
Nicola Ratto
Franca FagioliFranca Fagioli
Franca Fagioli
Genomic landscape of the four sarcoma subtypes. A and B, Box plots show the distribution of TMB on the y-axis, in which each dot represents an individual tumor sample. The horizontal dotted line at 1 mutation per megabase (mut/Mb) denotes the threshold used to separate lowly and highly mutated tumors. A, TMB distribution across all tumor samples of osteosarcoma (OS), Ewing sarcoma (EW), RMS, and SS. Statistically significant difference was observed between OS and EW samples (two-tailed Wilcoxon test). B, TMB distribution stratified by disease status (primary, recurrent, and metastasis) within the EW cohort. Significant differences were observed between primary and recurrent tumors (two-tailed Wilcoxon test) and between primary and metastatic tumors (two-tailed Wilcoxon test). C–F, Bar plots summarizing the top 25 mutated genes for each sarcoma subtypes, based on all tumor samples and without stratification by disease status. Genes are listed on the left side of each plot, with the corresponding percentage of mutated samples shown on the right. The percentages represent the number of unique samples harboring a mutation divided by the total number of samples in each sarcoma subtype (OS = 53, EW = 39, RMS = 13, and SS = 5). The x-axis shows the total number of mutations identified per gene. Color code represents the type of variants. G, Summary of the SBS and small indel signatures, stratified by disease status for each tumor subtype. On the left, the signature names. Each dot represents a mutational signature. The color of the dot (N) indicates the number of samples in which the signature is present, whereas the dot size represents the percentage of samples carrying that signature within that cohort. Signatures are grouped horizontally based on their classification and vertically by disease. The color bar at the bottom indicates the disease status.